A leap towards enforcing medicines prescribing by generic names in low- and middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies
The Drug Regulatory Authority of Pakistan (DRAP) in response to the public outcry on increasing medicines prices in the country issued notifications to direct healthcare professionals to prescribe medicines with their generic names. Like DRAP, many regulators in the low- and middle-income countries...
Saved in:
Main Authors: | Hamid A. Merchant (Author), Zaheer- (Author), Izhar M. Hussain (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ten recommendations to improve pharmacy practice in low and middle-income countries (LMICs)
by: Zaheer-
Published: (2021) -
Evaluation of performance-enhancing drugs seized by Israeli enforcement agencies 2012-2017: implications for policy and regulatory change
by: Hagit Bonny-Noach, et al.
Published: (2020) -
The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013) -
Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients' Access to Medicines
by: Oguzhan Koyuncu, et al.
Published: (2020) -
Coping with Forest and Land Fire Regulatory Challenges in Indonesia: an Assessment to the Regulatory Enforcement
by: Isna Fatimah
Published: (2018)